Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update
Journal of Clinical Oncology · 10.07.2023 · 41 (20) · 3652-3656
DOI: 10.1200/jco.23.00155 ↗Kurz gefasst
Leitlinie in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.07.2023. Verfasst von Katherine S Virgo und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Policy and Management, Rollins School of Public Health, Emory University, Atlanta, GA. Hauptthemen laut MEDLINE: Prostatic Neoplasms. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Health Policy and Management, Rollins School of Public Health, Emory University, Atlanta, GA.
- American Society of Clinical Oncology, Alexandria, VA.
- NantHealth Inc, Culver City, CA.
ORCID-Profile: Katherine S Virgo, R Bryan Rumble, James Talcott
Zitieren
APA
Virgo, K. S., Rumble, R. B., & Talcott, J. (2023). Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update. Journal of Clinical Oncology, 41(20), 3652-3656. https://doi.org/10.1200/jco.23.00155
Vancouver
Virgo KS, Rumble RB, Talcott J. Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update. Journal of Clinical Oncology. 2023;41(20):3652-3656. doi:10.1200/jco.23.00155
BibTeX
@article{Virgo2023,
author = {Virgo, Katherine S and Rumble, R Bryan and Talcott, James},
title = {Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update},
journal = {Journal of Clinical Oncology},
year = {2023},
volume = {41},
number = {20},
pages = {3652--3656},
doi = {10.1200/jco.23.00155}
}
EUVIMED